Dana Angelini is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 77 publications with 1,348 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JanssenProgram year20251 paymentResearch
- Janssen Scientific Affairs, LLCProgram year20253 payments
- GENZYME CORPORATIONProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
67%Factor Xa inhibitor59.3%Xarelto58%Eliquis42%Part D≥24 patientsLow Molecular Weight Heparin7.7%Enoxaparin Sodium100%Part D<11 patientsCancer & immunology
19.3%Antimetabolite19.3%Hydroxyurea100%Part D≥14 patientsMetabolism & gastrointestinal
8.7%Corticosteroid5%Prednisone100%Part D<11 patientsAmino Acid3.7%Endari100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Guidelines Can Be Lifesaving: The Vermont Model of Thromboprophylaxis Implementation
JCO Oncology Practice
2026 - Arterial and venous thromboembolism in hospitalized patients with COVID-19: a national multicenter cohort study
Blood Vessels Thrombosis & Hemostasis
2026 - Disease-specific safety and efficacy of DOACs vs LMWH for CAT in patients with brain metastases: a real-world analysis
Blood Vessels Thrombosis & Hemostasis
2026 - OC 20.3 Patients Educating Patients: A Scalable Patient-Led Webinar Model Integrating Patient and Clinician Expertise in Venous Thromboembolism Care
Research and Practice in Thrombosis and Haemostasis
2026 - Patient-centered management of heavy menstrual bleeding while on anticoagulation: A survey study
European Journal of Obstetrics & Gynecology and Reproductive Biology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Nissen, MD
Cleveland Clinic
Samir Kapadia, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Serpil Erzurum, MD
Cleveland Clinic
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”